REPL — Replimune Group, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737953 ·
Last close
$19.69
Market Cap
$1.87B
52W High
$23.54
52W Low
$1.50
ADV30
2,869,343
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -56,043,000 | -57,121,000 | 373,940,000 | 307,833,000 | 169,162,000 |
| Jun 2026 | 0 | — | -67,951,000 | -69,766,000 | 252,447,000 | 185,359,000 | 146,802,000 |
| Mar 2026 | 0 | — | -72,872,000 | -73,217,000 | 332,388,000 | 209,024,000 | 166,228,000 |
| Dec 2025 | 0 | — | -71,527,000 | -70,930,000 | 333,590,000 | 122,951,000 | 123,051,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-245,546,000
Investing CF
$221,382,000
Financing CF
$227,477,000
CapEx
$-223,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.93
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,389,406,000
Inventory
$9,867,000
Receivables
$0
ST Investments
$0
EBIT TTM
$-260,616,000
Pretax Income TTM
$-271,585,000
Interest Exp TTM
$10,969,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -318,315,000 | -313,940,000 | 332,388,000 | 166,228,000 | 166,160,000 | -280,344,000 |
| Mar 2025 | 0 | -259,854,000 | -247,297,000 | 551,328,000 | 135,485,000 | 415,843,000 | -192,250,000 |
| Mar 2024 | 0 | -232,853,000 | -215,794,000 | 487,722,000 | 113,214,000 | 374,508,000 | -185,467,000 |
| Mar 2023 | 0 | -174,166,000 | -174,284,000 | 646,591,000 | 91,299,000 | 555,292,000 | -128,050,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-297,013,000
OpCashFlow TTM
—
Assets (Latest)
$252,447,000
Forward EPS
$-0.67
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $19.00 · spot: $19.81 · call volume: 82 · put volume: 1,035
Expected Move to 2027-01-15:
±$5.10
(25.74%) —
implied range
$14.71 –
$24.91
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, Inc. | $1.83B | $39.06 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $1.93B | $7.50 | — |
| MAZE | Maze Therapeutics, Inc. | $1.80B | $32.87 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.69B | $2.72 | — |
| BEAM | Beam Therapeutics Inc. | $2.14B | $20.65 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet
2026-11-18 13:55 · Yahoo
How Investors May Respond To Replimune Group (REPL) Narrower Quarterly Loss
2026-11-05 08:19 · Yahoo
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
2026-11-02 13:55 · Yahoo
Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians
2026-10-29 18:41 · Yahoo
Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
2026-10-29 03:07 · Yahoo
Is Replimune Group (REPL) Cheap Following Its Reduced Net Loss Results?
2026-10-29 02:07 · Yahoo
Replimune: 3 Key Takeaways for Long-Term Investors
2026-10-29 01:33 · Yahoo
Replimune (REPL) Q2 2027 Earnings Call Transcript
2026-10-28 22:44 · Yahoo
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
2026-10-28 11:00 · Yahoo
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
2026-10-22 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.